Our institution has achieved a 99% minimal residual disease (MRD)-negative CR rate with co-administration of CD19 and CD22 CAR-T among children with B-ALL, seemingly better than results with single-targeted CD19 or CD22 and other dual-targeted structures [16–21]. The gene discussed is CD22; the disease is acute lymphoblastic leukemia.